This study is a 4-month open-label study of lithium in the acute treatment of patients with
bipolar I or II disorder. Eligible patients will receive lithium 300 mg twice daily and
titrated in 300 mg increments every 7 days as tolerated to levels > 0.6 mEq/L. Blood samples
are collected at baseline and at the end of study. Analyses of 45 molecule expressions in
mononuclear blood cells at baseline and endpoint will be carried out after the completion of
study. Fifty patients meeting Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)
criteria for bipolar I or II will be enrolled.
Phase:
Phase 4
Details
Lead Sponsor:
Keming Gao
Collaborators:
CellPrint Biotechnology National Alliance for Research on Schizophrenia and Depression